170 related articles for article (PubMed ID: 27933176)
1. Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation.
Larger E; Wewer Albrechtsen NJ; Hansen LH; Gelling RW; Capeau J; Deacon CF; Madsen OD; Yakushiji F; De Meyts P; Holst JJ; Nishimura E
Endocrinol Diabetes Metab Case Rep; 2016; 2016():. PubMed ID: 27933176
[TBL] [Abstract][Full Text] [Related]
2. Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis.
Galsgaard KD; Winther-Sørensen M; Ørskov C; Kissow H; Poulsen SS; Vilstrup H; Prehn C; Adamski J; Jepsen SL; Hartmann B; Hunt J; Charron MJ; Pedersen J; Wewer Albrechtsen NJ; Holst JJ
Am J Physiol Endocrinol Metab; 2018 Jan; 314(1):E93-E103. PubMed ID: 28978545
[TBL] [Abstract][Full Text] [Related]
3. The biology of glucagon and the consequences of hyperglucagonemia.
Wewer Albrechtsen NJ; Kuhre RE; Pedersen J; Knop FK; Holst JJ
Biomark Med; 2016 Nov; 10(11):1141-1151. PubMed ID: 27611762
[TBL] [Abstract][Full Text] [Related]
4. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor.
Zhou C; Dhall D; Nissen NN; Chen CR; Yu R
Pancreas; 2009 Nov; 38(8):941-6. PubMed ID: 19657311
[TBL] [Abstract][Full Text] [Related]
5. Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.
Kim J; Okamoto H; Huang Z; Anguiano G; Chen S; Liu Q; Cavino K; Xin Y; Na E; Hamid R; Lee J; Zambrowicz B; Unger R; Murphy AJ; Xu Y; Yancopoulos GD; Li WH; Gromada J
Cell Metab; 2017 Jun; 25(6):1348-1361.e8. PubMed ID: 28591637
[TBL] [Abstract][Full Text] [Related]
6. Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis.
Holst JJ; Wewer Albrechtsen NJ; Pedersen J; Knop FK
Diabetes; 2017 Feb; 66(2):235-240. PubMed ID: 28108603
[TBL] [Abstract][Full Text] [Related]
7. Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.
Okamoto H; Cavino K; Na E; Krumm E; Kim S; Stevis PE; Harp J; Murphy AJ; Yancopoulos GD; Gromada J
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2747-2752. PubMed ID: 28143927
[TBL] [Abstract][Full Text] [Related]
8. Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids.
Ohneda A; Parada E; Eisentraut AM; Unger RH
J Clin Invest; 1968 Oct; 47(10):2305-22. PubMed ID: 5676526
[TBL] [Abstract][Full Text] [Related]
9. The Liver-α-Cell Axis and Type 2 Diabetes.
Wewer Albrechtsen NJ; Pedersen J; Galsgaard KD; Winther-Sørensen M; Suppli MP; Janah L; Gromada J; Vilstrup H; Knop FK; Holst JJ
Endocr Rev; 2019 Oct; 40(5):1353-1366. PubMed ID: 30920583
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent effects of endogenous hyperglucagonemia on glucose homeostasis and hepatic glucagon action.
Lubaczeuski C; Bozadjieva-Kramer N; Louzada RA; Gittes GK; Leibowitz G; Bernal-Mizrachi E
JCI Insight; 2023 Jun; 8(11):. PubMed ID: 37140984
[TBL] [Abstract][Full Text] [Related]
11. Deleterious mutation V369M in the mouse GCGR gene causes abnormal plasma amino acid levels indicative of a possible liver-α-cell axis.
Liu Q; Lin G; Chen Y; Feng W; Xu Y; Lyu J; Yang D; Wang MW
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34002801
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
13. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis.
Suppli MP; Bagger JI; Lund A; Demant M; van Hall G; Strandberg C; Kønig MJ; Rigbolt K; Langhoff JL; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2020 Jun; 69(6):1090-1099. PubMed ID: 31974144
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
[TBL] [Abstract][Full Text] [Related]
15. The role of aminogenic glucagon secretion in blood glucose homeostasis.
Unger RH; Ohneda A; Aguilar-Parada E; Eisentraut AM
J Clin Invest; 1969 May; 48(5):810-22. PubMed ID: 5780193
[TBL] [Abstract][Full Text] [Related]
16. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
17. Glucagon cell hyperplasia and neoplasia: a recently recognized endocrine receptor disease.
Sipos B; Klöppel G
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37260318
[TBL] [Abstract][Full Text] [Related]
18. Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells.
Elmelund E; Galsgaard KD; Johansen CD; Trammell SAJ; Bomholt AB; Winther-Sørensen M; Hunt JE; Sørensen CM; Kruse T; Lau JF; Grevengoed TJ; Holst JJ; Wewer Albrechtsen NJ
iScience; 2022 Nov; 25(11):105296. PubMed ID: 36325048
[TBL] [Abstract][Full Text] [Related]
19. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.
Longuet C; Robledo AM; Dean ED; Dai C; Ali S; McGuinness I; de Chavez V; Vuguin PM; Charron MJ; Powers AC; Drucker DJ
Diabetes; 2013 Apr; 62(4):1196-205. PubMed ID: 23160527
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.
Wewer Albrechtsen NJ; Færch K; Jensen TM; Witte DR; Pedersen J; Mahendran Y; Jonsson AE; Galsgaard KD; Winther-Sørensen M; Torekov SS; Lauritzen T; Pedersen O; Knop FK; Hansen T; Jørgensen ME; Vistisen D; Holst JJ
Diabetologia; 2018 Mar; 61(3):671-680. PubMed ID: 29305624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
